<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014442</url>
  </required_header>
  <id_info>
    <org_study_id>ML22608</org_study_id>
    <secondary_id>2009-012231-15</secondary_id>
    <nct_id>NCT01014442</nct_id>
  </id_info>
  <brief_title>A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients</brief_title>
  <official_title>Pharmacokinetics of Mycophenolate Mofetil in de Novo Lung Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, single center study will assess the pharmacokinetics, efficacy and safety of
      mycophenolate mofetil in lung allograft recipients. Participants will be split into 2 groups
      according to the original disease: Group A (cystic fibrosis) and Group B (chronic obstructive
      pulmonary disease [COPD], emphysema, idiopathic pulmonary fibrosis, alpha-1 antitrypsin
      deficiency [A1AD]). All participants will receive mycophenolate mofetil orally, 1.5 grams (g)
      twice daily (BID) from Day 2 to 30 post transplantation, and 1 g BID from Day 31 to 90 post
      transplantation. Anticipated time on study treatment is 90 days, and target sample size is
      50-100 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 after transplantation</time_frame>
    <description>Cmax was expressed in milligrams per liter (mg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of MPA, MPAG and AcMPAG at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>Cmax was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of MPA, MPAG and AcMPAG at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>Cmax was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of MPA, MPAG and AcMPAG at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>Cmax was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>Cmax was expressed in micrograms per liter (mcg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>Cmax was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>Cmax was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>Cmax was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>Dose-normalized Cmax was determined (in 1 per liter [1/L]) by dividing the Cmax by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of MPA, MPAG, AcMPAG and Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Concentration (Cmin) of MPA, MPAG and AcMPAG at Day 4</measure>
    <time_frame>Predose (0 hour) on Day 4 post-transplantation</time_frame>
    <description>Cmin was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of MPA, MPAG and AcMPAG at Day 8</measure>
    <time_frame>Predose (0 hour) on Day 8 post-transplantation</time_frame>
    <description>Cmin was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of MPA, MPAG and AcMPAG at Day 20</measure>
    <time_frame>Predose (0 hour) on Day 20 post-transplantation</time_frame>
    <description>Cmin was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of MPA, MPAG and AcMPAG at Day 90</measure>
    <time_frame>Predose (0 hour) on Day 90 post-transplantation</time_frame>
    <description>Cmin was expressed in mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour) on Day 4 post-transplantation</time_frame>
    <description>Cmin was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour) on Day 8 post-transplantation</time_frame>
    <description>Cmin was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour) on Day 20 post-transplantation</time_frame>
    <description>Cmin was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour) on Day 90 post-transplantation</time_frame>
    <description>Cmin was expressed in mcg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vz) of MPA, MPAG and AcMPAG at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz of MPA, MPAG and AcMPAG at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz of MPA, MPAG and AcMPAG at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz of MPA, MPAG and AcMPAG at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of MPA, MPAG and AcMPAG at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in liters per hour (L/hour).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL of MPA, MPAG and AcMPAG at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL of MPA, MPAG and AcMPAG at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL of MPA, MPAG and AcMPAG at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to 12 Hours (AUC0-12) of MPA, MPAG and AcMPAG at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours time milligrams per liter (hours*[mg/L]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of MPA, MPAG and AcMPAG at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of MPA, MPAG and AcMPAG at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of MPA, MPAG and AcMPAG at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours times micrograms per liter (hours*[mcg/L]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 of Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Fraction of Free MPA at Day 4</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
    <description>MPA Free fraction (in percent [%]) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Fraction of Free MPA at Day 8</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
    <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Fraction of Free MPA at Day 20</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
    <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Fraction of Free MPA at Day 90</measure>
    <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
    <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) at Day 90 Post-Transplantation</measure>
    <time_frame>Day 90 post-transplantation</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Predicted FEV1 at Day 90 Post-Transplantation</measure>
    <time_frame>Day 90 post-transplantation</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Percent predicted FEV1 [%] = (FEV1 [L] / Predicted normal value FEV1 [L]) * 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at Day 90 Post-Transplantation</measure>
    <time_frame>Day 90 post-transplantation</time_frame>
    <description>FVC at Day 90 post-transplantation is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intracellular Adenosine-Tri-Phosphate (iATP) Levels</measure>
    <time_frame>Baseline, Days 4, 8, 20 and 90 post-transplantation</time_frame>
    <description>iATP was expressed in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in T-Cell Phenotype</measure>
    <time_frame>Baseline, Days 20 and 90 post-transplantation</time_frame>
    <description>Reported values are change in the T-cell phenotype status from baseline to Day 20 and 90 for cluster of differentiation (CD) 3, CD19, CD4, CD4CD25, CD28, CD45RA, CD45RO, CD69, CD127, and CD152.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Opportunistic Infections</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Opportunistic infections included all infections which occurred due to aspergillus, candida, pneumocystis, cryptococcus, listeria, herpes zoster, herpes simplex, cytomegalovirus pathogens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil; Cystic Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil; Other</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation</description>
    <arm_group_label>Mycophenolate Mofetil; Cystic Fibrosis</arm_group_label>
    <arm_group_label>Mycophenolate Mofetil; Other</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary single or bilateral lung allograft

          -  original disease cystic fibrosis, COPD, emphysema, idiopathic pulmonary fibrosis or
             A1AD

        Exclusion Criteria:

          -  lung allograft retransplantation

          -  multiple organ transplantation

          -  severe gastrointestinal disorder

          -  malignancies or history of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <results_first_submitted>December 19, 2016</results_first_submitted>
  <results_first_submitted_qc>December 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2017</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MMF - Cystic Fibrosis</title>
          <description>Participants with cystic fibrosis having transplantation at Day 0, received mycophenolate mofetil (MMF) capsules at dose of 1.5 grams (g) twice daily (BID) from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
        </group>
        <group group_id="P2">
          <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
          <description>Participants with chronic obstructive pulmonary disorder (COPD), emphysema, idiopathic pulmonary fibrosis (IPF), or alpha-1 antitrypsin deficiency (A1AD) having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all participants who received at least one dose of study drug and a safety follow-up, whether withdrawn prematurely or not.</population>
      <group_list>
        <group group_id="B1">
          <title>MMF - Cystic Fibrosis</title>
          <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
        </group>
        <group group_id="B2">
          <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
          <description>Participants with COPD, emphysema, IPF or A1AD having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="7.42"/>
                    <measurement group_id="B2" value="54.3" spread="7.93"/>
                    <measurement group_id="B3" value="43.1" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4</title>
        <description>Cmax was expressed in milligrams per liter (mg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 after transplantation</time_frame>
        <population>Per Protocol (PP) Population: Intent-to treat (ITT) population (received at least one dose of study drug and where the primary variable was measured at least once under study drug) excluding participants with major protocol violations (total 46 participants). Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4</title>
          <description>Cmax was expressed in milligrams per liter (mg/L).</description>
          <population>Per Protocol (PP) Population: Intent-to treat (ITT) population (received at least one dose of study drug and where the primary variable was measured at least once under study drug) excluding participants with major protocol violations (total 46 participants). Number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.914" spread="5.46450"/>
                    <measurement group_id="O2" value="5.608" spread="2.5591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.210" spread="58.9632"/>
                    <measurement group_id="O2" value="91.207" spread="26.3876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.583" spread="0.9697"/>
                    <measurement group_id="O2" value="1.810" spread="0.8306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2649</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>1.305</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8300</ci_lower_limit>
            <ci_upper_limit>4.2500</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3113</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>11.405</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2000</ci_lower_limit>
            <ci_upper_limit>42.7800</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2953</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.305</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8100</ci_lower_limit>
            <ci_upper_limit>0.1900</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of MPA, MPAG and AcMPAG at Day 8</title>
        <description>Cmax was expressed in mg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of MPA, MPAG and AcMPAG at Day 8</title>
          <description>Cmax was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.124" spread="4.2748"/>
                    <measurement group_id="O2" value="6.106" spread="3.3663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.127" spread="54.0215"/>
                    <measurement group_id="O2" value="100.128" spread="25.1228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" spread="0.5914"/>
                    <measurement group_id="O2" value="1.361" spread="0.9163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1308</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9900</ci_lower_limit>
            <ci_upper_limit>0.4100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4886</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-10.845</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.5000</ci_lower_limit>
            <ci_upper_limit>20.7900</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2218</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6000</ci_lower_limit>
            <ci_upper_limit>0.1900</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of MPA, MPAG and AcMPAG at Day 20</title>
        <description>Cmax was expressed in mg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of MPA, MPAG and AcMPAG at Day 20</title>
          <description>Cmax was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.284" spread="3.8472"/>
                    <measurement group_id="O2" value="6.762" spread="3.7405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.882" spread="37.6112"/>
                    <measurement group_id="O2" value="124.450" spread="45.0613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.624" spread="0.3895"/>
                    <measurement group_id="O2" value="1.434" spread="1.0501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0886</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7900</ci_lower_limit>
            <ci_upper_limit>0.2800</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0220</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-30.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.9700</ci_lower_limit>
            <ci_upper_limit>-6.3600</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0200</ci_lower_limit>
            <ci_upper_limit>-0.2700</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of MPA, MPAG and AcMPAG at Day 90</title>
        <description>Cmax was expressed in mg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of MPA, MPAG and AcMPAG at Day 90</title>
          <description>Cmax was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.915" spread="9.2479"/>
                    <measurement group_id="O2" value="7.294" spread="3.1817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.938" spread="44.6135"/>
                    <measurement group_id="O2" value="113.453" spread="48.2935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.375" spread="0.6514"/>
                    <measurement group_id="O2" value="1.163" spread="0.6856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>3.945</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2500</ci_lower_limit>
            <ci_upper_limit>8.2300</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7144</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-7.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.1900</ci_lower_limit>
            <ci_upper_limit>30.7000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of AcMPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3930</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3100</ci_lower_limit>
            <ci_upper_limit>0.8800</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Free MPA at Day 4</title>
        <description>Cmax was expressed in micrograms per liter (mcg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Free MPA at Day 4</title>
          <description>Cmax was expressed in micrograms per liter (mcg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.275" spread="133.2231"/>
                    <measurement group_id="O2" value="84.014" spread="57.8348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Free MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3002</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>17.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5000</ci_lower_limit>
            <ci_upper_limit>74.3200</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Free MPA at Day 8</title>
        <description>Cmax was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Free MPA at Day 8</title>
          <description>Cmax was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.571" spread="35.1104"/>
                    <measurement group_id="O2" value="95.553" spread="62.6051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Free MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0334</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-25.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.2500</ci_lower_limit>
            <ci_upper_limit>-2.2900</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Free MPA at Day 20</title>
        <description>Cmax was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Free MPA at Day 20</title>
          <description>Cmax was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.822" spread="39.9533"/>
                    <measurement group_id="O2" value="100.094" spread="120.8269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Free MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1151</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-23.805</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.2700</ci_lower_limit>
            <ci_upper_limit>5.9700</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Free MPA at Day 90</title>
        <description>Cmax was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Free MPA at Day 90</title>
          <description>Cmax was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.293" spread="97.6509"/>
                    <measurement group_id="O2" value="101.472" spread="93.9834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of Free MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5974</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-15.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.8800</ci_lower_limit>
            <ci_upper_limit>30.5600</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
        <description>Dose-normalized Cmax was determined (in 1 per liter [1/L]) by dividing the Cmax by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
          <description>Dose-normalized Cmax was determined (in 1 per liter [1/L]) by dividing the Cmax by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>1/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00557" spread="0.003907"/>
                    <measurement group_id="O2" value="0.00422" spread="0.001924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08286" spread="0.037461"/>
                    <measurement group_id="O2" value="0.06749" spread="0.017478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001122" spread="0.0006350"/>
                    <measurement group_id="O2" value="0.001388" spread="0.0007160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000929" spread="0.00008796"/>
                    <measurement group_id="O2" value="0.0000625" spread="0.00003907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5466</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00103</ci_lower_limit>
            <ci_upper_limit>0.00259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3223</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.00728</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00707</ci_lower_limit>
            <ci_upper_limit>0.03161</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2108</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00070</ci_lower_limit>
            <ci_upper_limit>0.00012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of Free MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called a Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4334</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0000112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000140</ci_lower_limit>
            <ci_upper_limit>0.0000462</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
        <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
          <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>1/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00356" spread="0.002769"/>
                    <measurement group_id="O2" value="0.00435" spread="0.002522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06980" spread="0.033524"/>
                    <measurement group_id="O2" value="0.07070" spread="0.017856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000702" spread="0.0003736"/>
                    <measurement group_id="O2" value="0.000967" spread="0.0006297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000409" spread="0.00002274"/>
                    <measurement group_id="O2" value="0.0000663" spread="0.00004075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1511</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00216</ci_lower_limit>
            <ci_upper_limit>0.00030</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4131</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00695</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02050</ci_lower_limit>
            <ci_upper_limit>0.01103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2677</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00046</ci_lower_limit>
            <ci_upper_limit>0.00013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of Free MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0000185</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000394</ci_lower_limit>
            <ci_upper_limit>-0.0000050</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
        <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
          <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>1/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00395" spread="0.002619"/>
                    <measurement group_id="O2" value="0.00456" spread="0.002462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07044" spread="0.029284"/>
                    <measurement group_id="O2" value="0.08430" spread="0.029430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000482" spread="0.0003487"/>
                    <measurement group_id="O2" value="0.000969" spread="0.0006947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000439" spread="0.00004750"/>
                    <measurement group_id="O2" value="0.0000666" spread="0.00008052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3784</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00063</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00230</ci_lower_limit>
            <ci_upper_limit>0.00084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0942</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.01602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03229</ci_lower_limit>
            <ci_upper_limit>0.00297</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00062</ci_lower_limit>
            <ci_upper_limit>-0.00015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of Free MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1760</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0000126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000328</ci_lower_limit>
            <ci_upper_limit>-0.0000091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
        <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized Cmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
          <description>Dose-normalized Cmax was determined (in 1/L) by dividing the Cmax by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>1/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01261" spread="0.007644"/>
                    <measurement group_id="O2" value="0.00742" spread="0.003631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10671" spread="0.037035"/>
                    <measurement group_id="O2" value="0.10948" spread="0.030395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001377" spread="0.0006935"/>
                    <measurement group_id="O2" value="0.001134" spread="0.0005100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000945" spread="0.00009640"/>
                    <measurement group_id="O2" value="0.0001043" spread="0.00009208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0509</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00027</ci_lower_limit>
            <ci_upper_limit>0.00833</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8262</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00567</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03414</ci_lower_limit>
            <ci_upper_limit>0.02671</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4345</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.00023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00030</ci_lower_limit>
            <ci_upper_limit>0.00070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized Cmax of Free MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6472</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000586</ci_lower_limit>
            <ci_upper_limit>0.0000364</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.823" spread="1.1626"/>
                    <measurement group_id="O2" value="2.892" spread="2.9202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.713" spread="2.4167"/>
                    <measurement group_id="O2" value="4.891" spread="2.6546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.379" spread="1.2344"/>
                    <measurement group_id="O2" value="3.405" spread="1.9162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.472" spread="0.3758"/>
                    <measurement group_id="O2" value="1.405" spread="0.4644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5745</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9500</ci_lower_limit>
            <ci_upper_limit>0.5000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2003</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3333</ci_lower_limit>
            <ci_upper_limit>0.0833</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of AcMPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0929</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0833</ci_lower_limit>
            <ci_upper_limit>0.0000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of Free MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0823</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0000</ci_lower_limit>
            <ci_upper_limit>0.0667</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.138" spread="1.4976"/>
                    <measurement group_id="O2" value="1.659" spread="0.9530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.669" spread="1.4773"/>
                    <measurement group_id="O2" value="3.647" spread="1.4555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.802" spread="1.2418"/>
                    <measurement group_id="O2" value="2.546" spread="1.1508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.272" spread="0.5982"/>
                    <measurement group_id="O2" value="1.446" spread="0.3638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8106</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0417</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5000</ci_lower_limit>
            <ci_upper_limit>1.7333</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1667</ci_lower_limit>
            <ci_upper_limit>0.1667</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6311</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0667</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3333</ci_lower_limit>
            <ci_upper_limit>1.4667</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of Free MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4330</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1667</ci_lower_limit>
            <ci_upper_limit>0.0167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.293" spread="1.9048"/>
                    <measurement group_id="O2" value="2.463" spread="1.8928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.762" spread="2.2954"/>
                    <measurement group_id="O2" value="4.907" spread="2.8568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.842" spread="1.7915"/>
                    <measurement group_id="O2" value="3.411" spread="1.8799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.236" spread="0.6144"/>
                    <measurement group_id="O2" value="1.366" spread="0.4692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1667</ci_lower_limit>
            <ci_upper_limit>0.5833</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4947</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0833</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0000</ci_lower_limit>
            <ci_upper_limit>0.0833</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4425</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.1667</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9667</ci_lower_limit>
            <ci_upper_limit>0.2000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of Free MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9720</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0500</ci_lower_limit>
            <ci_upper_limit>0.0333</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.450" spread="0.5251"/>
                    <measurement group_id="O2" value="2.143" spread="2.2487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.095" spread="1.7884"/>
                    <measurement group_id="O2" value="4.420" spread="1.9078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.234" spread="1.0899"/>
                    <measurement group_id="O2" value="3.564" spread="2.3686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.490" spread="0.0666"/>
                    <measurement group_id="O2" value="1.485" spread="0.5282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8834</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1667</ci_lower_limit>
            <ci_upper_limit>0.7000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0386</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-1.8333</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2000</ci_lower_limit>
            <ci_upper_limit>0.0000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0558</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.525</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6167</ci_lower_limit>
            <ci_upper_limit>0.0000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tmax of Free MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2333</ci_lower_limit>
            <ci_upper_limit>-0.0667</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Concentration (Cmin) of MPA, MPAG and AcMPAG at Day 4</title>
        <description>Cmin was expressed in mg/L.</description>
        <time_frame>Predose (0 hour) on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Concentration (Cmin) of MPA, MPAG and AcMPAG at Day 4</title>
          <description>Cmin was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.267" spread="1.0082"/>
                    <measurement group_id="O2" value="1.094" spread="0.8473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.917" spread="41.3384"/>
                    <measurement group_id="O2" value="47.493" spread="17.9747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.602" spread="0.5628"/>
                    <measurement group_id="O2" value="0.733" spread="0.4686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5224</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2600</ci_lower_limit>
            <ci_upper_limit>0.5000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2088</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>11.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2900</ci_lower_limit>
            <ci_upper_limit>30.2900</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1794</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4500</ci_lower_limit>
            <ci_upper_limit>0.0800</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of MPA, MPAG and AcMPAG at Day 8</title>
        <description>Cmin was expressed in mg/L.</description>
        <time_frame>Predose (0 hour) on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of MPA, MPAG and AcMPAG at Day 8</title>
          <description>Cmin was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" spread="0.6136"/>
                    <measurement group_id="O2" value="0.772" spread="0.3482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.566" spread="51.2379"/>
                    <measurement group_id="O2" value="57.189" spread="20.8518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.386" spread="0.4870"/>
                    <measurement group_id="O2" value="0.517" spread="0.2623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4027</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3800</ci_lower_limit>
            <ci_upper_limit>0.1900</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0875</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-16.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.3500</ci_lower_limit>
            <ci_upper_limit>6.3900</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0112</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3500</ci_lower_limit>
            <ci_upper_limit>-0.0500</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of MPA, MPAG and AcMPAG at Day 20</title>
        <description>Cmin was expressed in mg/L.</description>
        <time_frame>Predose (0 hour) on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of MPA, MPAG and AcMPAG at Day 20</title>
          <description>Cmin was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.782" spread="0.5945"/>
                    <measurement group_id="O2" value="1.234" spread="0.9971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.484" spread="29.5576"/>
                    <measurement group_id="O2" value="69.023" spread="25.6603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.261" spread="0.1662"/>
                    <measurement group_id="O2" value="0.528" spread="0.3977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0818</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5600</ci_lower_limit>
            <ci_upper_limit>0.0500</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0945</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-14.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.9000</ci_lower_limit>
            <ci_upper_limit>2.9400</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4100</ci_lower_limit>
            <ci_upper_limit>-0.0400</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of MPA, MPAG and AcMPAG at Day 90</title>
        <description>Cmin was expressed in mg/L.</description>
        <time_frame>Predose (0 hour) on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of MPA, MPAG and AcMPAG at Day 90</title>
          <description>Cmin was expressed in mg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.103" spread="0.7446"/>
                    <measurement group_id="O2" value="1.570" spread="1.0282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.957" spread="32.6863"/>
                    <measurement group_id="O2" value="80.488" spread="37.2631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.449" spread="0.3552"/>
                    <measurement group_id="O2" value="0.466" spread="0.3096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3289</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1400</ci_lower_limit>
            <ci_upper_limit>0.2800</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1243</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-20.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.3900</ci_lower_limit>
            <ci_upper_limit>4.7100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmin of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8704</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2800</ci_lower_limit>
            <ci_upper_limit>0.2300</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of Free MPA at Day 4</title>
        <description>Cmin was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour) on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Free MPA at Day 4</title>
          <description>Cmin was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.188" spread="37.9357"/>
                    <measurement group_id="O2" value="23.711" spread="14.6991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4043</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>5.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0100</ci_lower_limit>
            <ci_upper_limit>24.4900</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of Free MPA at Day 8</title>
        <description>Cmin was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour) on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Free MPA at Day 8</title>
          <description>Cmin was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.161" spread="16.3831"/>
                    <measurement group_id="O2" value="15.669" spread="9.6168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8930</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0700</ci_lower_limit>
            <ci_upper_limit>8.0100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of Free MPA at Day 20</title>
        <description>Cmin was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour) on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Free MPA at Day 20</title>
          <description>Cmin was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.193" spread="9.1443"/>
                    <measurement group_id="O2" value="20.237" spread="16.2117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0819</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-4.935</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3100</ci_lower_limit>
            <ci_upper_limit>1.1100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of Free MPA at Day 90</title>
        <description>Cmin was expressed in mcg/L.</description>
        <time_frame>Predose (0 hour) on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Free MPA at Day 90</title>
          <description>Cmin was expressed in mcg/L.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.102" spread="3.3201"/>
                    <measurement group_id="O2" value="18.831" spread="12.6155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0414</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-8.205</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2700</ci_lower_limit>
            <ci_upper_limit>-0.0700</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vz) of MPA, MPAG and AcMPAG at Day 4</title>
        <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz) of MPA, MPAG and AcMPAG at Day 4</title>
          <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.46" spread="182.247"/>
                    <measurement group_id="O2" value="287.74" spread="237.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.681" spread="4.7587"/>
                    <measurement group_id="O2" value="12.062" spread="3.7316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1065.02" spread="611.137"/>
                    <measurement group_id="O2" value="705.38" spread="502.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1552</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>69.7186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.4659</ci_lower_limit>
            <ci_upper_limit>162.9545</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6057</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.7836</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2675</ci_lower_limit>
            <ci_upper_limit>2.5529</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0188</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>299.1021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.5869</ci_lower_limit>
            <ci_upper_limit>695.1789</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz of MPA, MPAG and AcMPAG at Day 8</title>
        <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz of MPA, MPAG and AcMPAG at Day 8</title>
          <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.45" spread="260.837"/>
                    <measurement group_id="O2" value="331.51" spread="150.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.168" spread="5.1048"/>
                    <measurement group_id="O2" value="12.740" spread="5.2593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1432.88" spread="919.423"/>
                    <measurement group_id="O2" value="1173.38" spread="708.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0659</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>88.959</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7876</ci_lower_limit>
            <ci_upper_limit>209.0183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7842</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.4456</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1366</ci_lower_limit>
            <ci_upper_limit>2.2920</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4072</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>121.3737</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-233.6483</ci_lower_limit>
            <ci_upper_limit>560.0069</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz of MPA, MPAG and AcMPAG at Day 20</title>
        <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz of MPA, MPAG and AcMPAG at Day 20</title>
          <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.06" spread="267.025"/>
                    <measurement group_id="O2" value="257.57" spread="126.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.798" spread="5.1535"/>
                    <measurement group_id="O2" value="9.533" spread="3.1984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3006.18" spread="2570.205"/>
                    <measurement group_id="O2" value="1571.93" spread="1944.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0040</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>207.9933</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.2442</ci_lower_limit>
            <ci_upper_limit>355.1739</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0689</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>2.6186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1999</ci_lower_limit>
            <ci_upper_limit>6.7766</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0306</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>635.7812</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.4696</ci_lower_limit>
            <ci_upper_limit>2793.7642</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz of MPA, MPAG and AcMPAG at Day 90</title>
        <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz of MPA, MPAG and AcMPAG at Day 90</title>
          <description>Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.48" spread="78.679"/>
                    <measurement group_id="O2" value="192.53" spread="226.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.254" spread="4.6738"/>
                    <measurement group_id="O2" value="9.201" spread="4.4274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811.15" spread="404.733"/>
                    <measurement group_id="O2" value="980.49" spread="473.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9029</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>4.7477</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.5212</ci_lower_limit>
            <ci_upper_limit>59.8304</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9692</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6739</ci_lower_limit>
            <ci_upper_limit>3.9521</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vz of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3744</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-149.7962</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-644.4526</ci_lower_limit>
            <ci_upper_limit>311.9735</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance (CL) of MPA, MPAG and AcMPAG at Day 4</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in liters per hour (L/hour).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of MPA, MPAG and AcMPAG at Day 4</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in liters per hour (L/hour).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>L/hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.471" spread="32.7611"/>
                    <measurement group_id="O2" value="56.709" spread="22.3503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6754" spread="0.81910"/>
                    <measurement group_id="O2" value="1.7615" spread="0.46573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.60" spread="151.301"/>
                    <measurement group_id="O2" value="140.96" spread="110.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1362</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>7.8422</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9110</ci_lower_limit>
            <ci_upper_limit>18.4444</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4325</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.1609</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5693</ci_lower_limit>
            <ci_upper_limit>0.2710</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0316</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>47.2686</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1970</ci_lower_limit>
            <ci_upper_limit>112.7806</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL of MPA, MPAG and AcMPAG at Day 8</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>CL of MPA, MPAG and AcMPAG at Day 8</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.921" spread="33.7184"/>
                    <measurement group_id="O2" value="81.578" spread="63.7936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3235" spread="1.55336"/>
                    <measurement group_id="O2" value="1.7847" spread="0.75624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.86" spread="448.947"/>
                    <measurement group_id="O2" value="253.81" spread="237.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0572</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estmator</param_type>
            <param_value>19.0536</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4250</ci_lower_limit>
            <ci_upper_limit>35.3852</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3198</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.3541</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2524</ci_lower_limit>
            <ci_upper_limit>1.1097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0845</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>54.0322</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7706</ci_lower_limit>
            <ci_upper_limit>160.3469</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL of MPA, MPAG and AcMPAG at Day 20</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>CL of MPA, MPAG and AcMPAG at Day 20</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.068" spread="27.7321"/>
                    <measurement group_id="O2" value="58.295" spread="19.5800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9338" spread="0.69979"/>
                    <measurement group_id="O2" value="1.4788" spread="0.44488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.68" spread="614.970"/>
                    <measurement group_id="O2" value="232.34" spread="179.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>25.0037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.2373</ci_lower_limit>
            <ci_upper_limit>43.5102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0277</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.4297</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0340</ci_lower_limit>
            <ci_upper_limit>0.9925</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>318.5455</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>154.1902</ci_lower_limit>
            <ci_upper_limit>526.1716</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL of MPA, MPAG and AcMPAG at Day 90</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>CL of MPA, MPAG and AcMPAG at Day 90</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body and expressed in L/hour.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>L/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.091" spread="20.9125"/>
                    <measurement group_id="O2" value="36.922" spread="15.2129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5701" spread="0.99265"/>
                    <measurement group_id="O2" value="1.2433" spread="0.53337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.28" spread="218.455"/>
                    <measurement group_id="O2" value="223.56" spread="191.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9417</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.579</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.5052</ci_lower_limit>
            <ci_upper_limit>11.6346</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2941</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.1817</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1954</ci_lower_limit>
            <ci_upper_limit>0.6246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8170</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-4.9076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-84.8234</ci_lower_limit>
            <ci_upper_limit>109.9321</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to 12 Hours (AUC0-12) of MPA, MPAG and AcMPAG at Day 4</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours time milligrams per liter (hours*[mg/L]).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to 12 Hours (AUC0-12) of MPA, MPAG and AcMPAG at Day 4</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours time milligrams per liter (hours*[mg/L]).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*(mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.460" spread="7.8103"/>
                    <measurement group_id="O2" value="27.174" spread="10.4909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1095.98" spread="659.211"/>
                    <measurement group_id="O2" value="829.14" spread="281.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.414" spread="7.5535"/>
                    <measurement group_id="O2" value="13.672" spread="6.6349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2798</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-2.4102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5642</ci_lower_limit>
            <ci_upper_limit>3.0044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4063</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>72.7203</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-107.1596</ci_lower_limit>
            <ci_upper_limit>393.5295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0441</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-3.6042</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1854</ci_lower_limit>
            <ci_upper_limit>-0.1887</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 8</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 8</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*(mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.841" spread="8.2077"/>
                    <measurement group_id="O2" value="23.352" spread="10.7853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881.50" spread="634.587"/>
                    <measurement group_id="O2" value="888.96" spread="277.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.064" spread="4.2591"/>
                    <measurement group_id="O2" value="9.081" spread="6.5063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0510</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-5.8077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7302</ci_lower_limit>
            <ci_upper_limit>0.0033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2733</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-171.159</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-361.4437</ci_lower_limit>
            <ci_upper_limit>171.9652</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0718</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-1.9621</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8456</ci_lower_limit>
            <ci_upper_limit>0.2067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 20</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 20</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*(mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.925" spread="10.7674"/>
                    <measurement group_id="O2" value="28.290" spread="10.5485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="812.65" spread="391.881"/>
                    <measurement group_id="O2" value="1095.37" spread="391.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.252" spread="2.2066"/>
                    <measurement group_id="O2" value="9.482" spread="6.6815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-8.6964</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7713</ci_lower_limit>
            <ci_upper_limit>-4.6498</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-268.9537</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-506.7782</ci_lower_limit>
            <ci_upper_limit>-77.3970</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-4.828</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1455</ci_lower_limit>
            <ci_upper_limit>-2.6133</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 90</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of MPA, MPAG and AcMPAG at Day 90</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hours*(mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.365" spread="16.4658"/>
                    <measurement group_id="O2" value="31.864" spread="15.5442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776.28" spread="385.310"/>
                    <measurement group_id="O2" value="972.69" spread="530.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.776" spread="5.0791"/>
                    <measurement group_id="O2" value="7.219" spread="5.2217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7144</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>1.7477</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1010</ci_lower_limit>
            <ci_upper_limit>14.6563</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3413</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-156.3255</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-526.0765</ci_lower_limit>
            <ci_upper_limit>195.8348</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC0-12 of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6251</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.888</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0288</ci_lower_limit>
            <ci_upper_limit>4.2273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of Free MPA at Day 4</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours times micrograms per liter (hours*[mcg/L]).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of Free MPA at Day 4</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours times micrograms per liter (hours*[mcg/L]).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.703" spread="120.4152"/>
                    <measurement group_id="O2" value="80.272" spread="45.9523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2342</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>24.315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.0292</ci_lower_limit>
            <ci_upper_limit>79.3650</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of Free MPA at Day 8</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of Free MPA at Day 8</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.155" spread="26.0913"/>
                    <measurement group_id="O2" value="83.683" spread="51.4228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1964</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-13.5592</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.3950</ci_lower_limit>
            <ci_upper_limit>5.4825</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of Free MPA at Day 20</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of Free MPA at Day 20</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.530" spread="30.3408"/>
                    <measurement group_id="O2" value="89.315" spread="90.3819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0672</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-22.7878</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.8217</ci_lower_limit>
            <ci_upper_limit>3.7573</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-12 of Free MPA at Day 90</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 of Free MPA at Day 90</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours and expressed in hours*(mcg/L).</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>hours*mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.874" spread="64.6536"/>
                    <measurement group_id="O2" value="99.212" spread="81.0812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2453</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-21.4737</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.1567</ci_lower_limit>
            <ci_upper_limit>8.5708</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 4</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hours/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01652" spread="0.004684"/>
                    <measurement group_id="O2" value="0.02016" spread="0.007383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7720" spread="0.42519"/>
                    <measurement group_id="O2" value="0.6165" spread="0.20281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00739" spread="0.005002"/>
                    <measurement group_id="O2" value="0.01056" spread="0.005828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000943" spread="0.00008029"/>
                    <measurement group_id="O2" value="0.0000594" spread="0.00003237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1362</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00734</ci_lower_limit>
            <ci_upper_limit>0.00106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 MPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4325</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.04797</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08467</ci_lower_limit>
            <ci_upper_limit>0.26322</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of AcMPAG at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0316</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00311</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00645</ci_lower_limit>
            <ci_upper_limit>-0.00029</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of Free MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3269</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0000158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000134</ci_lower_limit>
            <ci_upper_limit>0.0000552</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 8</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hours/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01256" spread="0.005018"/>
                    <measurement group_id="O2" value="0.01624" spread="0.007077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6157" spread="0.40835"/>
                    <measurement group_id="O2" value="0.6270" spread="0.18884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00426" spread="0.002733"/>
                    <measurement group_id="O2" value="0.00644" spread="0.004471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000428" spread="0.00001807"/>
                    <measurement group_id="O2" value="0.0000580" spread="0.00003330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0572</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00383</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00761</ci_lower_limit>
            <ci_upper_limit>0.00010</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3198</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.09626</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25269</ci_lower_limit>
            <ci_upper_limit>0.11464</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of AcMPAG at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0845</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00131</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00352</ci_lower_limit>
            <ci_upper_limit>0.00013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of Free MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1769</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.00001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000250</ci_lower_limit>
            <ci_upper_limit>0.0000043</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 20</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hours/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01402" spread="0.007208"/>
                    <measurement group_id="O2" value="0.01923" spread="0.007029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6059" spread="0.28149"/>
                    <measurement group_id="O2" value="0.7440" spread="0.26032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00239" spread="0.001707"/>
                    <measurement group_id="O2" value="0.00642" spread="0.004432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000399" spread="0.00003632"/>
                    <measurement group_id="O2" value="0.0000597" spread="0.00006020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00876</ci_lower_limit>
            <ci_upper_limit>-0.00148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0277</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.14764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31026</ci_lower_limit>
            <ci_upper_limit>-0.01067</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of AcMPAG at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00476</ci_lower_limit>
            <ci_upper_limit>0.00168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of Free MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1661</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0000138</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000295</ci_lower_limit>
            <ci_upper_limit>0.0000047</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
        <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-Normalized AUC0-12 of MPA, MPAG, AcMPAG and Free MPA at Day 90</title>
          <description>AUC0-12 is a measure of the serum concentration of the drug from time 0 to 12 hours. Dose-normalized AUC0-12 was determined (in hours/L) by dividing the AUC0-12 by the actual dose taken.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure. Number of participants with available data for specified category are provided against individual category.</population>
          <units>hours/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03126" spread="0.011529"/>
                    <measurement group_id="O2" value="0.03172" spread="0.012879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7887" spread="0.31007"/>
                    <measurement group_id="O2" value="0.9190" spread="0.31896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AcMPAG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00748" spread="0.004735"/>
                    <measurement group_id="O2" value="0.00700" spread="0.004084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free MPA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000752" spread="0.00006364"/>
                    <measurement group_id="O2" value="0.00001023" spread="0.00007888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9417</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.00054</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01037</ci_lower_limit>
            <ci_upper_limit>0.01042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of MPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2941</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.1461</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39951</ci_lower_limit>
            <ci_upper_limit>0.12988</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of AcMPAG at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8170</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.00033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00361</ci_lower_limit>
            <ci_upper_limit>0.00421</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose-Normalized AUC0-12 of Free MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1927</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodge-Lehmann estimator</param_type>
            <param_value>-0.0000239</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0000594</ci_lower_limit>
            <ci_upper_limit>0.0000154</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Fraction of Free MPA at Day 4</title>
        <description>MPA Free fraction (in percent [%]) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 4 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fraction of Free MPA at Day 4</title>
          <description>MPA Free fraction (in percent [%]) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of free fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5789" spread="0.42113"/>
                    <measurement group_id="O2" value="0.3208" spread="0.16486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Free Fraction of Free MPA at Day 4. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0821</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.1616</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0121</ci_lower_limit>
            <ci_upper_limit>0.4188</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Fraction of Free MPA at Day 8</title>
        <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 8 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fraction of Free MPA at Day 8</title>
          <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of free fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3595" spread="0.13517"/>
                    <measurement group_id="O2" value="0.3594" spread="0.20504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Free Fraction of Free MPA at Day 8. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3628</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0427</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0455</ci_lower_limit>
            <ci_upper_limit>0.1221</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Fraction of Free MPA at Day 20</title>
        <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 20 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fraction of Free MPA at Day 20</title>
          <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of free fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2922" spread="0.19811"/>
                    <measurement group_id="O2" value="0.3052" spread="0.22218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Free Fraction of Free MPA at Day 20. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9873</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>0.0010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1152</ci_lower_limit>
            <ci_upper_limit>0.1173</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Fraction of Free MPA at Day 90</title>
        <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
        <time_frame>Predose (0 hour), 0.5, 1, 1.5, 2, 4, 8, 10, and 12 hours post-dose on Day 90 post-transplantation</time_frame>
        <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Fraction of Free MPA at Day 90</title>
          <description>MPA Free fraction (in %) was calculated by dividing free MPA AUC0-12 by total MPA AUC0-12 times 100%.</description>
          <population>PP Population. Here, number of participants analyzed=participants who were evaluable for this outcome measure.</population>
          <units>percentage of free fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2270" spread="0.14614"/>
                    <measurement group_id="O2" value="0.3020" spread="0.13446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Free Fraction of Free MPA at Day 90. Analysis was performed using Wilcoxon rank sum test; corresponding p-value and point estimate (Hodges-Lehmann estimator) were calculated. The point estimator derived by sending the confidence level to zero is called as Hodges-Lehmann estimator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2178</p_value>
            <method>Wilcoxon rank sum test</method>
            <param_type>Hodges-Lehmann estimator</param_type>
            <param_value>-0.0857</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1870</ci_lower_limit>
            <ci_upper_limit>0.0265</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) at Day 90 Post-Transplantation</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
        <time_frame>Day 90 post-transplantation</time_frame>
        <population>ITT Population (total 64 participants). Here, Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) at Day 90 Post-Transplantation</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
          <population>ITT Population (total 64 participants). Here, Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.087" spread="0.9335"/>
                    <measurement group_id="O2" value="2.834" spread="0.6912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Predicted FEV1 at Day 90 Post-Transplantation</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Percent predicted FEV1 [%] = (FEV1 [L] / Predicted normal value FEV1 [L]) * 100%</description>
        <time_frame>Day 90 post-transplantation</time_frame>
        <population>ITT Population. Here, Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Predicted FEV1 at Day 90 Post-Transplantation</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Percent predicted FEV1 [%] = (FEV1 [L] / Predicted normal value FEV1 [L]) * 100%</description>
          <population>ITT Population. Here, Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.75" spread="19.743"/>
                    <measurement group_id="O2" value="90.17" spread="20.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at Day 90 Post-Transplantation</title>
        <description>FVC at Day 90 post-transplantation is reported.</description>
        <time_frame>Day 90 post-transplantation</time_frame>
        <population>ITT Population. Here, Number of participants analyzed = participants evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at Day 90 Post-Transplantation</title>
          <description>FVC at Day 90 post-transplantation is reported.</description>
          <population>ITT Population. Here, Number of participants analyzed = participants evaluable for the outcome measure.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.445" spread="0.9499"/>
                    <measurement group_id="O2" value="3.619" spread="1.0388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intracellular Adenosine-Tri-Phosphate (iATP) Levels</title>
        <description>iATP was expressed in ng/mL.</description>
        <time_frame>Baseline, Days 4, 8, 20 and 90 post-transplantation</time_frame>
        <population>ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome measure. Here n= participants who were evaluable for each category, for respective arm groups.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intracellular Adenosine-Tri-Phosphate (iATP) Levels</title>
          <description>iATP was expressed in ng/mL.</description>
          <population>ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome measure. Here n= participants who were evaluable for each category, for respective arm groups.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="223.32"/>
                    <measurement group_id="O2" value="85.4" spread="215.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.9" spread="294.53"/>
                    <measurement group_id="O2" value="144.9" spread="286.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.4" spread="382.87"/>
                    <measurement group_id="O2" value="-45.9" spread="199.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-164.6" spread="312.98"/>
                    <measurement group_id="O2" value="-114.7" spread="138.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in T-Cell Phenotype</title>
        <description>Reported values are change in the T-cell phenotype status from baseline to Day 20 and 90 for cluster of differentiation (CD) 3, CD19, CD4, CD4CD25, CD28, CD45RA, CD45RO, CD69, CD127, and CD152.</description>
        <time_frame>Baseline, Days 20 and 90 post-transplantation</time_frame>
        <population>ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome measure. Here n= participants who were evaluable for each category, for respective arm groups.</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in T-Cell Phenotype</title>
          <description>Reported values are change in the T-cell phenotype status from baseline to Day 20 and 90 for cluster of differentiation (CD) 3, CD19, CD4, CD4CD25, CD28, CD45RA, CD45RO, CD69, CD127, and CD152.</description>
          <population>ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome measure. Here n= participants who were evaluable for each category, for respective arm groups.</population>
          <units>percentage of lymphocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="13.012"/>
                    <measurement group_id="O2" value="-3.01" spread="13.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="11.433"/>
                    <measurement group_id="O2" value="-2.81" spread="6.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="10.554"/>
                    <measurement group_id="O2" value="1.88" spread="8.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="5.322"/>
                    <measurement group_id="O2" value="0.61" spread="6.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="15.626"/>
                    <measurement group_id="O2" value="-14.71" spread="24.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="26.054"/>
                    <measurement group_id="O2" value="-1.93" spread="13.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4CD25: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="6.877"/>
                    <measurement group_id="O2" value="-0.53" spread="0.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4CD25: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="1.354"/>
                    <measurement group_id="O2" value="-0.10" spread="0.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD28: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="10.105"/>
                    <measurement group_id="O2" value="-4.44" spread="7.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD28: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.15" spread="25.362"/>
                    <measurement group_id="O2" value="-1.04" spread="6.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RA: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="15.802"/>
                    <measurement group_id="O2" value="-5.11" spread="17.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RA: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="12.498"/>
                    <measurement group_id="O2" value="-4.88" spread="13.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RO: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="4.199"/>
                    <measurement group_id="O2" value="-2.83" spread="3.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RO: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="7.564"/>
                    <measurement group_id="O2" value="-0.43" spread="7.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="10.031"/>
                    <measurement group_id="O2" value="0.01" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD69: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="10.040"/>
                    <measurement group_id="O2" value="-0.04" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD127: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="13.566"/>
                    <measurement group_id="O2" value="-3.90" spread="7.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD127: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="14.603"/>
                    <measurement group_id="O2" value="-2.03" spread="12.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD152: Change at Day 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.78" spread="17.562"/>
                    <measurement group_id="O2" value="-10.97" spread="17.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD152: Change at Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="2.624"/>
                    <measurement group_id="O2" value="-15.59" spread="29.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Opportunistic Infections</title>
        <description>Opportunistic infections included all infections which occurred due to aspergillus, candida, pneumocystis, cryptococcus, listeria, herpes zoster, herpes simplex, cytomegalovirus pathogens.</description>
        <time_frame>Up to Day 90</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>MMF - Cystic Fibrosis</title>
            <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
          </group>
          <group group_id="O2">
            <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
            <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Opportunistic Infections</title>
          <description>Opportunistic infections included all infections which occurred due to aspergillus, candida, pneumocystis, cryptococcus, listeria, herpes zoster, herpes simplex, cytomegalovirus pathogens.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in rates</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>22.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to Day 90</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MMF - Cystic Fibrosis</title>
          <description>Participants with cystic fibrosis having transplantation at Day 0, received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 post-transplantation and then at 1 g BID from Day 31 to Day 90 post-transplantation.</description>
        </group>
        <group group_id="E2">
          <title>MMF - COPD, Emphysema, IPF, or A1AD</title>
          <description>Participants with COPD, emphysema, IPF or A1AD, having transplantation at Day 0 received MMF capsules at dose of 1.5 g BID from Day 2 to Day 30 and then at 1 g BID from Day 31 to Day 90.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis sclerosing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antibiotic resistant Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hydropneumorthorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperchromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antibody test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Klebsiella test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial polyp</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bronchostenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fibrinous bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

